A Novel Program to Accurately Quantify Infarction Volume by 99mTc MIBI SPECT, and Its Application for Re-Analyzing the Effect of Erythropoietin Administration in Patients With Acute Myocardial Infarction – A Randomized Controlled Pilot Trial of the EPO/AMI-I Study –

Norihiko Yoshimura; Ken Toba; Takuya Ozawa; Yoshifusa Aizawa; Tetsuo Hosoya

doi:10.1253/circj.CJ-10-0912

Rapid Communication

A Novel Program to Accurately Quantify Infarction Volume by ^99mTc MIBI SPECT, and Its Application for Re-Analyzing the Effect of Erythropoietin Administration in Patients With Acute Myocardial Infarction

– A Randomized Controlled Pilot Trial of the EPO/AMI-I Study –

Norihiko Yoshimura, Ken Toba, Takuya Ozawa, Yoshifusa Aizawa, Tetsuo Hosoya

Author information

Keywords: Acute myocardial infarction, Erythropoietin, Single-photon emission computed tomography

JOURNAL FREE ACCESS

2010 Volume 74 Issue 12 Pages 2741-2743

DOI https://doi.org/10.1253/circj.CJ-10-0912

View "Advance Publication" version (November 2, 2010).

Details

Abstract

Background: This study aimed to apply a software to calculate myocardial infarction (MI) volume by single-photon emission computed tomography. Methods and Results: The cardioVol software has been developed to reconstruct 3D figures from sequential short axis images. We re-analyzed the data from the EPO/AMI-I Study. The MI volume at baseline correlated with maximum creatine kinase. The MI volume significantly decreased during the 6-month follow up in the erythropoietin (EPO) group, but not in the control group. The decrements of MI volume in the EPO group were significantly larger than those in the control group. Conclusions: The efficacy of EPO was further confirmed by the software. (Circ J 2010; 74: 2741-2743)

Corresponding author

Register with J-STAGE for free!